Insiders Mendus AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:29:37 13/05/2024 BST			5-day change	1st Jan Change
0.485 ^SEK	+5.66%		+6.48%	-7.27%

04-16	Mendus AB Announces Board Changes	CI
03-27	Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	CI

Mendus AB Announces Board Changes	04-16	CI
Mendus AB Appoints Ted Fjällman as Board Member	12-13	CI
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting	11-17	CI
Mendus AB Appoints Lewis Lanier to Scientific Advisory Board	20/06/23	CI
Mendus AB: Mendus announces Nomination Committee for the 2023 Annual General Meeting	10/11/22	GL
Mendus AB Announces Nomination Committee for 2023 Annual General Meeting	10/11/22	CI
Immunicum AB has Changed its Name to Mendus AB	23/06/22	CI
Immunicum AB Appoints Leopold Bertea as Chief Technology Officer	05/05/22	CI
Immunicum Announces Nomination Committee for the 2022 Annual General Meeting	03/11/21	AQ
Immunicum AB Appoints Nomination Committee for the 2022 Annual General Meeting	03/11/21	CI
Immunicum Appoints Interim CFO On Permanent Basis	26/10/21	MT
Immunicum AB Appoints Lotta Ferm as Chief Financial Officer	26/10/21	CI
Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board	30/09/21	CI
Immunicum AB Announces Board Changes	04/05/21	CI
Immunicum AB Announces Updated Executive Management Team After Business Combination	16/03/21	CI
Immunicum AB Appoints Erik Manting as Chief Executive Officer	16/03/21	CI
Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer	01/03/21	CI
Immunicum AB Approves Election of New Board Members	22/01/21	CI
Immunicum AB Announces Transitions in Board of Directors	21/01/21	CI
Immunicum : Changes to the Nomination Committee for Immunicum AB	30/12/20	AQ

No results for this search